Location History:
- Edison, NJ (US) (2011 - 2012)
- Rahway, NJ (US) (2017)
Company Filing History:
3 out of 2,405 
1 out of 47 
1 out of 7 
Years Active: 2011-2017
Title: The Innovations of Ranabir Sinha Roy
Introduction
Ranabir Sinha Roy is a notable inventor based in Edison, NJ (US). He has made significant contributions to the field of metabolic disorder treatments, particularly focusing on diabetes and obesity. With a total of 3 patents, his work has garnered attention in the pharmaceutical industry.
Latest Patents
One of his latest patents involves oxyntomodulin analogs, which are peptide analogs of oxyntomodulin (OXM, glucagon-37). These analogs have been modified to resist cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV), thereby increasing their in vivo half-life. This innovation allows the peptide analogs to function as dual GLP-1/glucagon receptor (GCGR) agonists, making them useful for treating metabolic disorders such as diabetes and obesity. Another significant patent is for a pharmaceutical composition comprising oxyntomodulin derivatives, which can also be utilized for the treatment of metabolic diseases.
Career Highlights
Ranabir has worked with prominent companies in the pharmaceutical sector, including Merck Sharp & Dohme Corporation and Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. His experience in these organizations has contributed to his expertise in developing innovative treatments for metabolic disorders.
Collaborations
Throughout his career, Ranabir has collaborated with esteemed colleagues such as Elisabetta Bianchi and Antonello Pessi. These partnerships have played a crucial role in advancing his research and patent developments.
Conclusion
Ranabir Sinha Roy's contributions to the field of metabolic disorder treatments through his innovative patents highlight his importance as an inventor. His work continues to pave the way for advancements in pharmaceutical compositions aimed at combating diabetes and obesity.